

Nina Shah

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3339786/publications.pdf>

Version: 2024-02-01

130
papers

4,696
citations

172386

29
h-index

114418

63
g-index

135
all docs

135
docs citations

135
times ranked

4926
citing authors

#	ARTICLE	IF	CITATIONS
1	Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2021, 384, 705-716.	13.9	1,129
2	Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. <i>Blood</i> , 2020, 136, 936-945.	0.6	436
3	B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. <i>Leukemia</i> , 2020, 34, 985-1005.	3.3	253
4	Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 589-597.	0.8	184
5	Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 177, 457-466.	1.2	158
6	Antigen Presenting Cell-Mediated Expansion of Human Umbilical Cord Blood Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity. <i>PLoS ONE</i> , 2013, 8, e76781.	1.1	155
7	Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1915-1925.	2.0	130
8	Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1163-1171.	2.0	105
9	Concise Review: Umbilical Cord Blood Transplantation: Past, Present, and Future. <i>Stem Cells Translational Medicine</i> , 2014, 3, 1435-1443.	1.6	75
10	Results of a 2â€arm, phase 2 clinical trial using postâ€transplantation cyclophosphamide for the prevention of graftâ€versusâ€host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. <i>Cancer</i> , 2016, 122, 3316-3326.	2.0	75
11	Feasibility of autologous hematopoietic stem cell transplant in patients aged â‰¥70 years with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2012, 53, 118-122.	0.6	74
12	Durable remission with salvage second autotransplants in patients with multiple myeloma. <i>Cancer</i> , 2012, 118, 3549-3555.	2.0	69
13	Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e266-e275.	2.2	68
14	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 642-649.	0.6	65
15	Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy. <i>Blood</i> , 2018, 132, 488-488.	0.6	61
16	Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. <i>Blood</i> , 2016, 128, 297-312.	0.6	54
17	Third-party umbilical cord bloodâ€derived regulatory T cells prevent xenogenic graft-versus-host disease. <i>Cytotherapy</i> , 2014, 16, 90-100.	0.3	53
18	General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1284-1290.	2.0	51

#	ARTICLE	IF	CITATIONS
19	Novel Techniques for Ex Vivo Expansion of Cord Blood: Clinical Trials. <i>Frontiers in Medicine</i> , 2015, 2, 89.	1.2	50
20	Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. <i>Cancer</i> , 2016, 122, 2680-2688.	2.0	48
21	Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. <i>Circulation Research</i> , 2021, 128, 1780-1801.	2.0	48
22	Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. <i>Cancer</i> , 2020, 126, 5077-5087.	2.0	47
23	Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1914-1920.	2.0	46
24	Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 6-20.	0.6	45
25	Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. <i>Cytotherapy</i> , 2014, 16, 84-89.	0.3	42
26	Subclinical Peripheral Neuropathy in Patients With Multiple Myeloma Before Chemotherapy Is Correlated With Decreased Fingertip Innervation Density. <i>Journal of Clinical Oncology</i> , 2014, 32, 3156-3162.	0.8	37
27	Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 906-912.	2.0	35
28	Impact of t(11;14)(q13;q32) on the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1227-1232.	2.0	34
29	Better allele-level matching improves transplant-related mortality after double cord blood transplantation. <i>Haematologica</i> , 2015, 100, 1361-1370.	1.7	32
30	Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma. <i>Blood Advances</i> , 2022, 6, 1309-1318.	2.5	31
31	Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 687-693.	0.2	29
32	Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. <i>Cancer</i> , 2016, 122, 3831-3837.	2.0	27
33	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. , 2020, 8, e000734.		27
34	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. <i>Leukemia</i> , 2020, 34, 3338-3347.	3.3	27
35	Estimation of minimally important differences and responder definitions for EORTC QLQ-C15-PY20 scores in multiple myeloma patients. <i>European Journal of Haematology</i> , 2019, 103, 500-509.	1.1	25
36	Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 285-292.	2.0	24

#	ARTICLE	IF	CITATIONS
37	DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma. <i>Leukemia</i> , 2020, 34, 938-941.	3.3	24
38	Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. <i>Lancet Haematology</i> , 2018, 5, e532-e542.	2.2	23
39	Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database. <i>Cancer</i> , 2020, 126, 808-813.	2.0	23
40	Umbilical cord blood-derived cellular products for cancer immunotherapy. <i>Cytotherapy</i> , 2015, 17, 739-748.	0.3	22
41	Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1359-1366.	2.0	22
42	The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements. <i>PLoS ONE</i> , 2020, 15, e0237155.	1.1	21
43	CAR T-cell therapy: is it prime time in myeloma?. <i>Blood Advances</i> , 2019, 3, 3473-3480.	2.5	21
44	Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. <i>Blood Advances</i> , 2020, 4, 2163-2171.	2.5	21
45	Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. <i>Bone Marrow Transplantation</i> , 2019, 54, 1089-1093.	1.3	20
46	Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. <i>Blood Advances</i> , 2020, 4, 3295-3301.	2.5	20
47	Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 668-678.	1.0	20
48	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance. <i>Blood</i> , 2021, 138, 79-79.	0.6	20
49	High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. <i>Lancet Haematology</i> , 2017, 4, e283-e292.	2.2	19
50	Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 126.	6.9	19
51	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy. <i>Blood</i> , 2020, 136, 45-46.	0.6	19
52	Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. <i>European Journal of Haematology</i> , 2017, 99, 532-535.	1.1	18
53	Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 683-688.	2.0	18
54	Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 430.e1-430.e7.	0.6	18

#	ARTICLE	IF	CITATIONS
55	Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1607-1615.	0.6	17
56	CAR T-cell therapy: is it prime time in myeloma?. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 260-265.	0.9	17
57	Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. <i>American Journal of Hematology</i> , 2016, 91, E442-7.	2.0	16
58	Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 5344-5348.	2.5	16
59	Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 961-965.	2.0	15
60	Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 226-231.	2.0	15
61	High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. <i>Leukemia and Lymphoma</i> , 2019, 60, 442-452.	0.6	15
62	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. <i>Cancer</i> , 2021, 127, 82-92.	2.0	15
63	Pre-clinical development of TNB-383B, a fully human T-cell engaging bispecific antibody targeting BCMA for the treatment of multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8034-8034.	0.8	15
64	Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 581-587.	2.0	14
65	Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1784-1802.	2.0	14
66	Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 122-128.	0.2	12
67	Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 477.e1-477.e7.	0.6	12
68	Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. <i>Cancer</i> , 2017, 123, 3568-3575.	2.0	11
69	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2443-2449.	2.0	11
70	Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1039-1044.	2.0	11
71	ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 284-293.	0.6	11
72	A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1211-1219.	0.6	10

#	ARTICLE	IF	CITATIONS
73	Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies. <i>Future Oncology</i> , 2021, 17, 3549-3560.	1.1	10
74	Evidence-Based Mini-Review: Treatment Options for Patients with Relapsed/Refractory Myeloma Previously Treated with Novel Agents and High-Dose Chemotherapy and Autologous Stem-Cell Transplantation. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 310-313.	0.9	9
75	Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. <i>Cancer</i> , 2021, 127, 1816-1826.	2.0	9
76	When and How to Treat Relapsed Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 358-375.	1.8	9
77	Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome. <i>Leukemia and Lymphoma</i> , 2021, 62, 2600-2611.	0.6	9
78	Molecular and Phenotypic Profiling of Drug Product and Post-Infusion Samples from CRB-402, an Ongoing: Phase I Clinical Study of bb21217 a BCMA-Directed CAR T Cell Therapy. <i>Blood</i> , 2020, 136, 3-4.	0.6	9
79	Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. <i>Blood</i> , 2015, 126, 3155-3155.	0.6	9
80	Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 83.e1-83.e9.	0.6	9
81	Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 737-749.	0.6	9
82	Lenalidomide-Induced Graft-Vs.-Leukemia Effect in a Patient With Chronic Lymphocytic Leukemia Who Relapsed After Allogeneic Stem Cell Transplant. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e105-e109.	0.2	8
83	Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2020, 191, 442-452.	1.2	8
84	Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older. <i>Cancer</i> , 2021, 127, 4233-4239.	2.0	8
85	Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. <i>British Journal of Haematology</i> , 2017, 177, 567-577.	1.2	7
86	Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies. <i>Blood</i> , 2021, 138, 2852-2852.	0.6	7
87	Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma. <i>Transfusion</i> , 2017, 57, 1052-1057.	0.8	6
88	Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma. <i>European Journal of Haematology</i> , 2017, 98, 263-268.	1.1	6
89	Incidence, management and outcomes of arterial and venous thrombosis after chimeric antigen receptor modified T cells for B cell lymphoma and multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1003-1006.	0.6	6
90	Healthcare Costs Incurred by Patients with Multiple Myeloma Following Triple Class Exposure (TCE) in the US. <i>Oncology and Therapy</i> , 2021, 9, 659-669.	1.0	6

#	ARTICLE	IF	CITATIONS
91	Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial. <i>Blood</i> , 2021, 138, 1739-1739.	0.6	6
92	Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma. <i>Quality of Life Research</i> , 2018, 27, 979-985.	1.5	5
93	Circulating Plasma Cells By Routine Complete Blood Count Identify Patients With Similar Outcome As Plasma Cell Leukemia. <i>Blood</i> , 2013, 122, 5356-5356.	0.6	5
94	A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids. <i>Blood</i> , 2015, 126, 854-854.	0.6	5
95	A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. <i>Leukemia and Lymphoma</i> , 2018, 59, 515-518.	0.6	4
96	Modified Hyper-CVAD With Proteasome Inhibition for Multiple Myeloma: A Single-Center Retrospective Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e961-e985.	0.2	4
97	Plasmablastic Lymphoma: 28 Patient Single Institution Experience. <i>Blood</i> , 2013, 122, 4310-4310.	0.6	4
98	Feasibility of a Smartphone-Based Health Coaching Intervention for Patient Self-Management of Nutrition in the Post-Chemotherapy Setting. <i>Blood</i> , 2016, 128, 3554-3554.	0.6	4
99	Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2022, 57, 31-37.	1.3	4
100	Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells. <i>Frontiers in Oncology</i> , 2021, 11, 783703.	1.3	4
101	Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): A post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN. <i>Journal of Clinical Oncology</i> , 2022, 40, 8011-8011.	0.8	4
102	Umbilical cord blood: advances and opportunities. <i>Cytotherapy</i> , 2015, 17, 693-694.	0.3	3
103	Benzodiazepine and zolpidem prescriptions during autologous stem cell transplantation. <i>EJHaem</i> , 2021, 2, 276-279.	0.4	3
104	Subcutaneous daratumumab (DARA SC) plus lenalidomide versus lenalidomide alone as maintenance therapy in patients (pts) with newly diagnosed multiple myeloma (NDMM) who are minimal residual disease (MRD) positive after frontline autologous stem cell transplant (ASCT): The phase 3 AURIGA study. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS8054-TPS8054.	0.8	3
105	Evaluation of subcutaneous daratumumab injections in the ambulatory care setting. <i>Journal of Oncology Pharmacy Practice</i> , 2021, , 107815522110469.	0.5	3
106	Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin. <i>Blood</i> , 2021, 138, 2723-2723.	0.6	3
107	Digital Life Coaching During Stem Cell Transplantation: Development and Usability Study. <i>JMIR Formative Research</i> , 2022, 6, e33701.	0.7	3
108	A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan vs. fludarabine and once daily IV busulfan and clofarabine in allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 0, , .	1.3	3

#	ARTICLE	IF	CITATIONS
109	Progress in Novel Cellular Therapy Options for Chronic Lymphocytic Leukemia: The MD Anderson Perspective. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S18-S22.	0.2	2
110	Lenalidomide Treatment Enhances Immunological Synapse Formation of Cord Blood Natural Killer Cells with B Cells Derived From Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011, 118, 1794-1794.	0.6	2
111	A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. <i>Bone Marrow Transplantation</i> , 2022, 57, 295-298.	1.3	2
112	Healthcare Costs of Multiple Myeloma Patients with Four or More Prior Lines of Therapy, Including Triple-Class Exposure in the United States. <i>Oncology and Therapy</i> , 2022, 10, 411-420.	1.0	2
113	Dramatic Reduction of Chronic Lymphocytic Leukemia (CLL) Cells Following Adoptive Transfer of Cord Blood (CB) Natural Killer (NK) Cells Using CB-Engrafted NOD-SCID IL2R β null (NSG) Mice as a Model.. <i>Blood</i> , 2009, 114, 2370-2370.	0.6	1
114	CD137L Reverse the Immunological Synapse Defects of Natural Killer Cells in Acute Myeloid Leukemia. <i>Blood</i> , 2011, 118, 246-246.	0.6	1
115	Impact of Non High-Risk Chromosomal Abnormalities on the Outcome of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2011, 118, 333-333.	0.6	1
116	Durable Remission and Survival in Relapsed/Refractory Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 5884-5884.	0.6	1
117	Increased Bone Marrow Plasma Cell Infiltration Pre-Transplant Is Associated with Worse Outcomes in Patients Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplantation for Multiple Myeloma,. <i>Blood</i> , 2011, 118, 4135-4135.	0.6	1
118	Role of Serum Lactate Dehydrogenase (LDH) As a Prognostic Marker for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.. <i>Blood</i> , 2012, 120, 3115-3115.	0.6	1
119	Gene Expression Profiling for Molecular Features of Response in a Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas. <i>Blood</i> , 2015, 126, 2705-2705.	0.6	1
120	HLA Homozygosity and Haplotype Bias Among Patients with Chronic Lymphocytic Leukemia: Implications for Disease Control by Physiologic Immune Surveillance. <i>Blood</i> , 2010, 116, 1370-1370.	0.6	0
121	Targeting Chronic Lymphocytic Leukemia with Cord Blood NK Cells In NSG Model. <i>Blood</i> , 2010, 116, 2453-2453.	0.6	0
122	Outcomes Among High Risk and Standard Risk Multiple Myeloma Patients Treated With High Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 3358-3358.	0.6	0
123	NK Cells Kill Myeloma Cells By Increasing ER Stress and Decreasing Autophagy Levels. NKG2D and NKP30 Are Involved In These Processes. <i>Blood</i> , 2013, 122, 3487-3487.	0.6	0
124	Use of Gene Expression Profiling May Predict Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting. <i>Blood</i> , 2015, 126, 5390-5390.	0.6	0
125	Comparable Outcomes of Therapy-Related and De Novo Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 2276-2276.	0.6	0
126	Title is missing!. , 2020, 15, e0237155.		0

#	ARTICLE	IF	CITATIONS
127	Title is missing!. , 2020, 15, e0237155.		0
128	Title is missing!. , 2020, 15, e0237155.		0
129	Title is missing!. , 2020, 15, e0237155.		0
130	Impact of second primary malignancy post-autologous hematopoietic stem cell transplantation on outcomes of multiple myeloma: A CIBMTR analysis.. Journal of Clinical Oncology, 2022, 40, 8057-8057.	0.8	0